Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Jiangxi Synergy Pharmaceutical (SZSE:300636) has had a rough month with its share price down 18%. But if you pay close attention, you might find that its key financial indicators look quite decent, which could mean that the stock could potentially rise in the long-term given how markets usually reward more resilient long-term fundamentals. Particularly, we will be paying attention to Jiangxi Synergy Pharmaceutical's ROE today.
江西协同药业(深圳证券交易所代码:300636)经历了艰难的一个月,其股价下跌了18%。但是,如果你密切关注,你可能会发现其关键财务指标看起来相当不错,考虑到市场通常会奖励更具弹性的长期基本面,这可能意味着该股有可能在长期内上涨。特别是,我们今天将关注江西协同药业的投资回报率。
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Put another way, it reveals the company's success at turning shareholder investments into profits.
股本回报率或投资回报率是对公司增值和管理投资者资金的有效性的考验。换句话说,它揭示了公司成功地将股东投资转化为利润。
Check out our latest analysis for Jiangxi Synergy Pharmaceutical
查看我们对江西协同药业的最新分析
How To Calculate Return On Equity?
如何计算股本回报率?
The formula for return on equity is:
股本回报率的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回报率 = 净利润(来自持续经营业务)÷ 股东权益
So, based on the above formula, the ROE for Jiangxi Synergy Pharmaceutical is:
因此,根据上述公式,江西协同制药的投资回报率为:
4.8% = CN¥105m ÷ CN¥2.2b (Based on the trailing twelve months to September 2023).
4.8% = 1.05亿元人民币 ÷ 22亿元人民币(基于截至2023年9月的过去十二个月)。
The 'return' is the amount earned after tax over the last twelve months. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.05 in profit.
“回报” 是过去十二个月的税后收入。这意味着,每持有价值1元人民币的股权,公司就会产生0.05元人民币的利润。
What Has ROE Got To Do With Earnings Growth?
投资回报率与收益增长有什么关系?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
我们已经确定,投资回报率是衡量公司未来收益的有效盈利指标。根据公司选择将多少利润进行再投资或 “保留”,我们便能够评估公司未来创造利润的能力。假设其他条件都一样,与功能不相同的公司相比,具有更高股本回报率和更高利润保留率的公司通常具有更高的增长率。
Jiangxi Synergy Pharmaceutical's Earnings Growth And 4.8% ROE
江西协同制药的收益增长和4.8%的投资回报率
It is hard to argue that Jiangxi Synergy Pharmaceutical's ROE is much good in and of itself. Not just that, even compared to the industry average of 8.5%, the company's ROE is entirely unremarkable. Despite this, surprisingly, Jiangxi Synergy Pharmaceutical saw an exceptional 25% net income growth over the past five years. We believe that there might be other aspects that are positively influencing the company's earnings growth. Such as - high earnings retention or an efficient management in place.
很难说江西协同药业的投资回报率本身就非常好。不仅如此,即使与8.5%的行业平均水平相比,该公司的投资回报率也完全不引人注目。尽管如此,令人惊讶的是,江西协同制药在过去五年中实现了惊人的25%的净收入增长。我们认为,可能还有其他方面对公司的收益增长产生积极影响。例如——高收益留存率或实行高效管理。
As a next step, we compared Jiangxi Synergy Pharmaceutical's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 11%.
下一步,我们将江西协同药业的净收入增长与行业进行了比较,令人高兴的是,我们发现该公司的增长高于行业平均增长11%。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240125/0-df0b8810037f1faa64ba6e295e60729e-0-2ff8e697960042f1dba65c9c5dc8339b.png/big)
Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. If you're wondering about Jiangxi Synergy Pharmaceutical's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
收益增长是股票估值的重要因素。无论情况如何,投资者都应设法确定预期的收益增长或下降是否已计入其中。通过这样做,他们将知道股票是走向清澈的蓝色海水,还是沼泽的水域在等着你。如果你想知道江西协同药业的估值,可以看看这个衡量其与行业相比的市盈率指标。
Is Jiangxi Synergy Pharmaceutical Making Efficient Use Of Its Profits?
江西协同制药在有效利用利润吗?
Jiangxi Synergy Pharmaceutical's ' three-year median payout ratio is on the lower side at 15% implying that it is retaining a higher percentage (85%) of its profits. This suggests that the management is reinvesting most of the profits to grow the business as evidenced by the growth seen by the company.
江西协同制药的三年中位数派息率处于较低水平,为15%,这意味着它保留了更高的利润百分比(85%)。这表明管理层正在将大部分利润再投资于业务增长,公司的增长就证明了这一点。
Moreover, Jiangxi Synergy Pharmaceutical is determined to keep sharing its profits with shareholders which we infer from its long history of six years of paying a dividend.
此外,江西协同药业决心继续与股东分享利润,这是我们从其六年派息的长期历史中推断出来的。
Summary
摘要
On the whole, we do feel that Jiangxi Synergy Pharmaceutical has some positive attributes. With a high rate of reinvestment, albeit at a low ROE, the company has managed to see a considerable growth in its earnings. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
总的来说,我们确实认为江西协同药业有一些积极的属性。尽管投资回报率很低,但由于再投资率很高,该公司的收益实现了可观的增长。既然如此,分析师的最新预测显示,该公司的收益将继续扩大。要了解有关公司未来收益增长预测的更多信息,请查看这份关于分析师预测的免费报告,以了解更多信息。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。